Nilutamide drug data and news

---

Combination Therapy To Avoid Prostate Cancer Recurrence  Sep 12, 2005
The anti-androgen hormone Nilutamide works by blocking the effects of excess testosterone, a hormone produced by the body that can promote the growth of cancer ... - MedIndia,

Combination Hormone/Vaccine Therapy for Prostate Cancer May ...  Aug 1, 2005
...randomly assigned 42 prostate cancer patients to receive either vaccine or second-line antiandrogen treatment, which consisted of the hormone nilutamide. ... - Kansas City infoZine

Dual therapy aids prostate patients  Jul 25, 2005
...assigned 42 prostate cancer patients to receive either the experimental vaccine or a second-line anti-androgen treatment, consisting of the hormone nilutamide. ... - Washington Times

Prostate Cancer Vaccine Boosts Hormone Therapy  Jul 25, 2005
The patients were randomly assigned to either a recombinant prostate cancer vaccine or Nilandron (nilutamide), a second-line hormone therapy, for six months. ... - MedPage Today

In vitro, nilutamide has been shown to inhibit the activity of liver cytochrome P-450 isoenzymes and therefore, may reduce the metabolism of compounds requiring these systems.
Consequently, drugs with a low therapeutic margin, such as vitamin K antagonists, phenytoin, and theophylline, could have a delayed elimination and increases in their serum half-life leading to a toxic level. The dosage of these drugs or others with a similar metabolism may need to be modified if they are administered concomitantly with nilutamide. For example, when vitamin K antagonists are administered concomitantly with nilutamide, prothrombin time should be carefully monitored and if necessary, the dosage of vitamin K antagonists should be reduced.